课题基金 / 基金详情

131 IODINE RADIOLABELED ANTI B1 MONOCLONAL ANTIBODY IN B CELL LYMPHOMA

131 IODINE RADIOLABELED ANTI B1 MONOCLONAL ANTIBODY IN B CELL LYMPHOMA
131 B 细胞淋巴瘤中的碘放射性标记抗 B1 单克隆抗体
批准号：
6244045
负责人：
MANSOOR N SALEH
金额：
$2.46万
依托单位：
UNIVERSITY OF ALABAMA AT BIRMINGHAM
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-02-10 至 1997-11-30
来源：
https://reporter.nih.gov/project-details/6244045
关键词：
B lymphocyte clinical research human subject human therapy evaluation iodine lymphoma monoclonal antibody neoplasm /cancer immunotherapy neoplasm /cancer radionuclide therapy neoplastic transformation nonHodgkin's lymphoma radiation dosage

项目摘要

项目成果

MANSOOR N SALEH的其他基金

相似基金

相关文献

中文摘要
翻译
这是一项单组开放标签研究，旨在验证剂量测定方法， 确定缓解率、治疗失败时间、安全性， 放射性标记抗-B1放射免疫治疗疗效和剂量测定 131碘治疗化疗难治性低度恶性肿瘤 非霍奇金B细胞淋巴瘤或经历过的低度淋巴瘤 从低级别到中级别或高级别的组织学转化 （转化淋巴瘤）。
英文摘要
This is a single-arm open-label study to verify dosimetry methods and determine the response rate, time to treatment failure, safety, efficacy, and dosimetry of radioimmunotherapy with Anti-B1 radiolabeled with 131 Iodine in patients who have chemotherapy-refractory low-grade non-Hodgkin's B-cell lymphoma or low-grade lymphoma which has undergone histologic transformation from low-grade to intermediate- or high-grade (transformed lymphoma).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
IDEC Y2B8 VS RITUXAN IN REFRACTORY LOW GRADE OR FOLLICULAR B CELL NON HODGKINS
ANTI C20 IDEC C2B8 (RITUXIMAB) IN AIDS ASSOCIATED NON HODGKINS LYMPHOMA
IDEC Y2B8 VS RITUXAN IN REFRACTORY LOW GRADE OR FOLLICULAR B CELL NON HODGKINS
ANTI C20 IDEC C2B8 (RITUXIMAB) IN AIDS ASSOCIATED NON HODGKINS LYMPHOMA
海外基金